CRI Lifetree, a specialized, multi-therapeutic early stage research company focused on pain, human abuse liability, psychiatry, neurology and diabetes, has opened a new state-of-the-art research facility in Marlton, N.J. The new site raises the company’s total bed count to 250 and adds capacity to conduct complex clinical trials.

“Because our facility is so close to Philadelphia, DIA gave us the opportunity to show many clients the site firsthand. The feedback was overwhelmingly positive!” said Larry Brownstein, head of corporate development, CRI Lifetree. “The recent visitors were pleased to see we have expanded our research space with this new, 60-bed, purpose-built facility.”

The additional bed space and added capabilities for conducting complex neurology, pediatrics and normal healthy patient studies comes at a time of considerable need for the industry. Other facility features include six beds dedicated to first-in-human studies. This space has an observation area to allow clinicians and sponsors the access needed. The new center also has separate areas for elderly and pediatric populations. The 21,000-square-foot building adds to CRI Lifetree’s two other facilities in Philadelphia and Salt Lake City.